Phase i study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors

British Journal of Cancer

Volumn 111, Issue 12, 2014, Pages 2268-2274

  Koczywas, M ^a   Frankel, P H ^a   Synold, T W ^a   Lenz, H J ^b   Mortimer, J E ^a   El Khoueiry, A B ^b   Gandara, D R ^c   Cristea, M C ^a   Chung, V M ^a   Lim, D ^a   Reckamp, K L ^a   Lau, D H ^c   Doyle, L A ^d   Ruel, C ^a   Carroll, M I ^a   Newman, E M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

advanced solid tumours; cisplatin; eribulin mesylate (E7389)

Indexed keywords

CISPLATIN; ERIBULIN; ANTINEOPLASTIC AGENT; ETHER DERIVATIVE; FURAN DERIVATIVE; HALICHONDRIN B; KETONE; MACROLIDE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GRADING; CANCER INCIDENCE; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DYSPHAGIA; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS CANCER; PARESTHESIA; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; MIDDLE AGED; NEOPLASMS; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ETHERS, CYCLIC; FURANS; HUMANS; KETONES; MACROLIDES; MIDDLE AGED; NEOPLASMS; YOUNG ADULT;

EID: 84927580970     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.554     Document Type: Article

References (19)

1. Amptoulach S, Tsavaris N (2011) Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011: 843019.
2. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266(24): 15882-15889.
3. Budman DR, Calabro A, Littlefield BA (2004) Synergistic combinations of E7389 (Halichondrin B analogue) with conventional agents: in vitro median effect analysis in cell lines with potential clinical implications. In: 27th Ann San Antonio Breast Cancer Symp [abst 6055].
4. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769): 914-923.
5. Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, Blunt JW, Munro MH, Gussio R, Hamel E (2006) Comparison of the activities of the truncated halichondrin B analogue NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70(6): 1866-1875.
6. Fillastre JP, Raguenez-Viotte G 1989) Cisplatin nephrotoxicity. Toxicol Lett 46 1,3 163-175.
7. Gatzemeier U, Von Powel J, Lee JS (1998) Phase III comparative study of high dose cisplatin vs. combination of paclitaxel and cisplatin in with advanced NSCLC. Proc Amer Soc Clin Oncol 17: 555a.
8. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15(12): 4207-4212.
9. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4(7): 1086-1095.
10. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analogue E7389. Cancer Res 64(16): 5760-5766.
11. Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubulestabilizing agents. J Clin Oncol 24(10): 1633-1642.
12. Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E (1993) Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr (15): 83-88.
13. Synold TW, Morgan RJ, Newman EM, Lenz HJ, Gandara DR, Colevas AD, Lewis MD, Doroshow JH (2005) A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial. J Clin Oncol 23(16): 200S-200S.
14. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P. National Cancer Institute Organ Dysfunction Working G (2007) Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13(12): 3660-3666.
15. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, Ashworth S, Rosen LS (2009) Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumours. Clin Cancer Res 15(12): 4213-4219.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216.
17. Tosca PJ, Bollinger LH, Merill JW (2008) Preclinical toxicology studies for halichondrin B macrocyclic ketone analogue E3789 (NSC-707389) in beagle dogs and rats [abstract 5422]. Proc Am Assoc Cancer Res 43: 1095.
18. Towle MJ, Nomoto K, Asano M, Kishi Y, Yu MJ, Littlefield BA (2012) Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. Anticancer Res 32(5): 1611-1619.
19. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61(3): 1013-1021.